Please use this identifier to cite or link to this item:
Title: Latin America validation of FACED score in patients with bronchiectasis: an analysis of six cohorts.
Authors: Athanazio, Rodrigo
Pereira, Mônica Corso
Gramblicka, Georgina
Cavalcanti-Lundgren, Fernando
de Figueiredo, Mara Fernandes
Arancibia, Francisco
Rached, Samia
de la Rosa, David
Máiz-Carro, Luis
Girón, Rosa
Olveira, Casilda
Prados, Concepción
Martinez-Garcia, Miguel Angel
Keywords: Bronchiectasis;FACED score;Mortality;Prognosis;Validation studies
metadata.dc.subject.mesh: Adult
Area Under Curve
Cause of Death
Disease Progression
Forced Expiratory Volume
Hospital Mortality
Kaplan-Meier Estimate
Latin America
Middle Aged
ROC Curve
Retrospective Studies
Risk Factors
Severity of Illness Index
Issue Date: 26-Apr-2017
Abstract: The FACED score is an easy-to-use multidimensional grading system that has demonstrated an excellent prognostic value for mortality in patients with bronchiectasis. A Spanish group developed the score but no multicenter international validation has yet been published. Retrospective and multicenter study conducted in six historical cohorts of patients from Latin America including 651 patients with bronchiectasis. Clinical, microbiological, functional, and radiological variables were collected, following the same criteria used in the original FACED score study. The vital status of all patients was determined in the fifth year of follow-up. The area under ROC curve (AUC-ROC) was used to calculate the predictive power of the FACED score for all-cause and respiratory deaths and both number and severity of exacerbations. The discriminatory power to divide patients into three groups of increasing severity was also analyzed. Mean (SD) age of 48.2 (16), 32.9% of males. The mean FACED score was 2.35 (1.68). During the follow up, 95 patients (14.6%) died (66% from respiratory causes). The AUC ROC to predict all-cause and respiratory mortality were 0.81 (95% CI: 0.77 to 0.85) 0.84 (95% CI: 0.80 to 0.88) respectively, and 0.82 (95% CI: 078-0.87) for at least one hospitalization per year. The division into three score groups separated bronchiectasis into distinct mortality groups (mild: 3.7%; moderate: 20.7% and severe: 48.5% mortality; p  The FACED score was confirmed as an excellent predictor of all-cause and respiratory mortality and severe exacerbations, as well as having excellent discriminative capacity for different degrees of severity in various bronchiectasis populations.
metadata.dc.identifier.doi: 10.1186/s12890-017-0417-3
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5406918.pdf703,17 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons